blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP0973741

EP0973741 - S-2'-(2-(1-METHYL-2-PIPERIDYL) ETHYL) CINNAMANILIDE AS A 5-HT2 RECEPTOR ANTAGONIST [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  16.04.2004
Database last updated on 19.07.2024
Most recent event   Tooltip22.04.2005Lapse of the patent in a contracting state
New state(s): LU
published on 08.06.2005  [2005/23]
Applicant(s)For all designated states
Amer, M. Samir
877 sandpoint Road
Carpenteria, CA 93013 / US
[N/P]
Former [2000/04]For all designated states
AMER, M. Samir
877 sandpoint Road
Carpenteria, CA 93013 / US
Inventor(s)01 / see applicant
...
[2000/04]
Representative(s)Ebner von Eschenbach, Jennifer, et al
Ladas & Parry LLP
Dachauerstrasse 37
80335 München / DE
[N/P]
Former [2002/09]Ebner von Eschenbach, Jennifer, et al
Ladas & Parry, Dachauerstrasse 37
80335 München / DE
Former [2000/04]Baillie, Iain Cameron, et al
Ladas & Parry, Dachauerstrasse 37
80335 München / DE
Application number, filing date98903668.623.01.1998
[2000/04]
WO1998US01304
Priority number, dateUS1997081050328.02.1997         Original published format: US 810503
[2000/04]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO9838165
Date:03.09.1998
Language:EN
[1998/35]
Type: A1 Application with search report 
No.:EP0973741
Date:26.01.2000
Language:EN
The application published by WIPO in one of the EPO official languages on 03.09.1998 takes the place of the publication of the European patent application.
[2000/04]
Type: B1 Patent specification 
No.:EP0973741
Date:11.06.2003
Language:EN
[2003/24]
Search report(s)International search report - published on:EP03.09.1998
ClassificationIPC:C07D211/26, A61K31/445
[2000/04]
CPC:
C07D211/26 (EP,KR,US); A61P17/02 (EP); A61P23/02 (EP);
A61P25/04 (EP); A61P43/00 (EP); A61P9/00 (EP);
A61P9/14 (EP) (-)
Designated contracting statesAT,   BE,   CH,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2000/04]
TitleGerman:S-2'-(2-(1-METHYL-2-PIPERIDYL) ETHYL) CINNAMANILIDE ALS 5-HT2 REZEPTOR ANTAGONIST[2000/04]
English:S-2'-(2-(1-METHYL-2-PIPERIDYL) ETHYL) CINNAMANILIDE AS A 5-HT2 RECEPTOR ANTAGONIST[2000/04]
French:S-2'-(2-(1-METHYL-2-PIPERIDYL)ETHYL)CINNAMANILIDE EN TANT QU'ANTAGONISTE DU RECEPTEUR DE 5-HT2[2000/04]
Entry into regional phase23.06.1999National basic fee paid 
23.06.1999Designation fee(s) paid 
23.06.1999Examination fee paid 
Examination procedure18.06.1998Request for preliminary examination filed
International Preliminary Examining Authority: US
23.06.1999Examination requested  [2000/04]
11.09.2000Despatch of a communication from the examining division (Time limit: M06)
13.03.2001Reply to a communication from the examining division
14.08.2001Despatch of a communication from the examining division (Time limit: M06)
18.02.2002Reply to a communication from the examining division
26.11.2002Date of oral proceedings
05.12.2002Minutes of oral proceedings despatched
13.12.2002Communication of intention to grant the patent
10.04.2003Fee for grant paid
10.04.2003Fee for publishing/printing paid
Opposition(s)12.03.2004No opposition filed within time limit [2004/23]
Fees paidRenewal fee
28.12.1999Renewal fee patent year 03
28.12.2000Renewal fee patent year 04
03.01.2002Renewal fee patent year 05
22.01.2003Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT11.06.2003
BE11.06.2003
FI11.06.2003
NL11.06.2003
DK11.09.2003
GR11.09.2003
PT11.09.2003
SE11.09.2003
IE23.01.2004
LU23.01.2004
MC31.01.2004
[2005/23]
Former [2005/03]AT11.06.2003
BE11.06.2003
FI11.06.2003
NL11.06.2003
DK11.09.2003
GR11.09.2003
PT11.09.2003
SE11.09.2003
IE23.01.2004
MC31.01.2004
Former [2005/02]AT11.06.2003
BE11.06.2003
FI11.06.2003
NL11.06.2003
DK11.09.2003
GR11.09.2003
PT11.09.2003
SE11.09.2003
MC31.01.2004
Former [2004/29]AT11.06.2003
BE11.06.2003
CH11.06.2003
FI11.06.2003
LI11.06.2003
NL11.06.2003
DK11.09.2003
GR11.09.2003
PT11.09.2003
SE11.09.2003
Former [2004/28]AT11.06.2003
BE11.06.2003
CH11.06.2003
FI11.06.2003
LI11.06.2003
NL11.06.2003
GR11.09.2003
PT11.09.2003
SE11.09.2003
Former [2004/10]AT11.06.2003
CH11.06.2003
FI11.06.2003
LI11.06.2003
NL11.06.2003
GR11.09.2003
PT11.09.2003
SE11.09.2003
Former [2004/05]AT11.06.2003
CH11.06.2003
FI11.06.2003
LI11.06.2003
NL11.06.2003
GR11.09.2003
PT11.09.2003
Former [2004/03]AT11.06.2003
CH11.06.2003
LI11.06.2003
NL11.06.2003
GR11.09.2003
PT11.09.2003
Former [2004/02]CH11.06.2003
LI11.06.2003
NL11.06.2003
GR11.09.2003
PT11.09.2003
Former [2004/01]CH11.06.2003
LI11.06.2003
Cited inInternational search[DXY]US4064254  (DYKSTRA STANLEY JOHN [US], et al) [DX] 1-4,8-25 * example 141 * * example 141A * [Y] 5-7;
 [DX]WO9418958  (SAM AMER & CO INC [US], et al) [DX] 8-25 * see compound I; page 11 *;
 [Y]WO9521819  (MERCK SHARP & DOHME [GB], et al) [Y] 5-7 * page 10, line 29 - line 30 * * page 28, line 23 - line 33 *;
 [Y]  - PORTOGHESE, PHILIP S. ET AL, "Stereochemical studies on medicinal agents. 13. Correlation of the solid-state conformations of 1,3,5-trimethyl- and 1,3-dimethyl-4-phenyl-4-propionoxypiperidine enantiomers with their absolute stereoselectivity at analgetic receptors", J. MED. CHEM. (1973), 16(3), 199-203 CODEN: JMCMAR, (1973), XP002061306 [Y] 5-7 * see optical resolution of compound 5 *

DOI:   http://dx.doi.org/10.1021/jm00261a006
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.